These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 2551437

  • 1. Successful treatment of CMV retinitis with ganciclovir after allogeneic marrow transplantation.
    Kaulfersch W, Urban C, Hauer C, Lackner H, Gamillscheg A, Slavc I, Langmann G.
    Bone Marrow Transplant; 1989 Sep; 4(5):587-9. PubMed ID: 2551437
    [Abstract] [Full Text] [Related]

  • 2. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA, Schmidt GM, Chao NJ, Rizk NW, Nademanee AP, Niland JC, Horak DA, Lee J, Gallez-Hawkins G, Kusnierz-Glaz CR.
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [Abstract] [Full Text] [Related]

  • 3. Treatment of cytomegalovirus (CMV) retinitis with intravitreous ganciclovir in HIV-infected children.
    Surachatkumtonekul T, Chokephaibulkit K, Vanprapar N, Pamonvaechavan P.
    J Med Assoc Thai; 2008 Mar; 91(3):331-7. PubMed ID: 18575285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CMV retinitis after cessation of ganciclovir therapy for CMV antigenemia in an unrelated BMT recipient.
    Suzuki N, Kudoh T, Mizue N, Watanabe J, Ikehata M, Tateno M, Ooguro H, Chiba S.
    Bone Marrow Transplant; 1998 Nov; 22(9):931-2. PubMed ID: 9827825
    [Abstract] [Full Text] [Related]

  • 6. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [Abstract] [Full Text] [Related]

  • 7. Effective pre-emptive therapy with Ganciclovir and specific immunoglobulins for CMV infection in a bone marrow transplanted patient.
    Dentamaro T, Volpi A, Cudillo L, Masi M, Tribalto M, Sordillo P, Salanitro A, Papa G.
    Haematologica; 1992 Apr; 77(3):284-6. PubMed ID: 1330849
    [Abstract] [Full Text] [Related]

  • 8. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA, Whimbey E, Champlin R, Abi-Said D, Przepiorka D, Tarrand J, Chan K, Bodey GP, Goodrich JM.
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [Abstract] [Full Text] [Related]

  • 9. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
    Bacigalupo A, van Lint MT, Tedone E, Moro F, Sanna MA, Longren M, Trespi G, Frassoni F, Occhini D, Gualandi F.
    Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
    [Abstract] [Full Text] [Related]

  • 10. Treatment and prophylaxis of cytomegalovirus disease.
    Levinson ML, Jacobson PA.
    Pharmacotherapy; 1992 Jun; 12(4):300-18. PubMed ID: 1325636
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, Ishida A, Iwao Y, Mukai M, Hibi T, Ikeda Y.
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [Abstract] [Full Text] [Related]

  • 14. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation.
    Singhal S, Mehta J, Powles R, Treleaven J, Horton C, Carrington D, Tryhorn Y, Jameson B.
    Bone Marrow Transplant; 1995 May; 15(5):777-81. PubMed ID: 7670405
    [Abstract] [Full Text] [Related]

  • 15. Ganciclovir implants: one year later.
    Cadman J.
    GMHC Treat Issues; 1997 May; 11(4/5):3-6. PubMed ID: 11364375
    [Abstract] [Full Text] [Related]

  • 16. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
    Ljungman P, Loré K, Aschan J, Klaesson S, Lewensohn-Fuchs I, Lönnqvist B, Ringdén O, Winiarski J, Ehrnst A.
    Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
    [Abstract] [Full Text] [Related]

  • 19. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
    Choi JH, Kim DW, Cho SG, Yoo JH, Jeong DC, Han CW, Shin WS, Min WS, Kim HK, Kim CC, Kim DJ.
    Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
    [Abstract] [Full Text] [Related]

  • 20. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
    Fujisaki T, Gondo H, Uchida N, Matsuo I, Takenaka K, Tanimoto K, Otsuka T, Minematsu T, Minamishima Y, Niho Y.
    Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.